|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
4.23/-1.52
|
Enterprise Value
3.05B
|
Balance Sheet |
Book Value Per Share
11.00
|
Cash Flow |
Cash Flow Yield
0.06
|
Income Statement |
Total Revenue
60.00M
|
Operating Revenue Per Share
--
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|

Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Itspipeline products include Rusfertide (PTG-300) and JNJ-2113. |